What Does the COVID-19 Vaccine Cost in 2026?

The COVID-19 vaccine market shifted from a federally-purchased, no-cost product to a standard commercial pharmaceutical starting in 2024, when the U.S. government's bulk-purchase contracts with Pfizer-BioNTech and Moderna expired. Comirnaty (Pfizer-BioNTech), Spikevax and mNexspike (Moderna), and Nuvaxovid (Novavax, approved in the U.S. in May 2025) now move through the same billing channels as any other vaccine: Medicare Part B, Medicaid, commercial insurance claims, or a cash-pay pharmacy visit. The FDA narrowed its 2025-2026 and 2026-2027 approvals to adults 65 and older and people 5 to 64 with at least one underlying condition that raises COVID-19 risk, such as diabetes, asthma, obesity, pregnancy, or a weakened immune system. Healthy people under 65 without a qualifying condition fall outside the FDA-labeled indication, which changes both pharmacy access and, in some states, insurance coverage.

Cash-pay pricing for the 2026-2027 formula runs from about $134 at the CDC's published federal reference price up to $299 at some retail pharmacy chains, before any separate administration fee. Medicare beneficiaries pay $0 because Congress placed COVID-19 vaccination under the Medicare Part B preventive-vaccine benefit in the CARES Act, the same statutory category as the flu and pneumococcal vaccines, so the $283 Part B deductible for 2026 never applies to this shot. Medicaid programs have covered ACIP-recommended adult vaccines, including COVID-19, with no cost-sharing since October 1, 2023, under a mandate in the Inflation Reduction Act. Commercially insured patients generally pay $0 too, as long as the shot is given in-network and the vaccine still carries an ACIP recommendation, even the narrower 2025 individual-decision-making recommendation that now applies to people under 65.

Pfizer, Moderna, and Novavax do not sell manufacturer copay cards for their COVID-19 vaccines the way they do for chronic-disease drugs, because insured patients already pay $0 by law and no prior authorization or formulary tier applies to an in-network Part B or ACA preventive vaccine. Instead, each company runs a separate access channel for the uninsured. Pfizer RxPathways supplies free Comirnaty through a patient's own doctor's office for households at or below 300% of the federal poverty level. Moderna routes free Spikevax and mNexspike doses through Direct Relief and Project HOPE, which supply Federally Qualified Health Centers and free clinics rather than accepting individual applications. This guide breaks down the 2026 cost by payer, the pharmacy price comparison, and what to do if you get an unexpected bill for a shot that should have cost $0.

What COVID-19 Vaccine Costs by Point of Pay (2026)

The price you pay depends almost entirely on WHERE you pay. The same covid-19 vaccine can cost many times more at a hospital than at your local pharmacy:

Why Hospitals Charge So Much

Hospitals rarely bill a standalone COVID-19 vaccine dose because most people get their shot at a retail pharmacy or physician's office, not during an inpatient stay. When a hospital does administer and bill a dose, usually for a patient already admitted for another reason, the charge can run several times the $230.41 Medicare product rate for Comirnaty. Facility fees, pharmacy handling charges, and nursing administration time get layered on top of the vaccine's acquisition cost, the same markup pattern seen with other injectable drugs given in a hospital setting.

Original Medicare pays the hospital the same $0 patient cost-share and a fixed product-plus-administration rate regardless of the facility's list price, so an inpatient charge of $500 or more for a single dose is a billing pattern worth disputing, not a true out-of-pocket cost. Ask for an itemized bill and the CPT code (91320 for Comirnaty, 91322 for Spikevax, 91323 for mNexspike, or 91304 for Nuvaxovid), and confirm the claim was submitted to Part B rather than billed as a self-pay cash charge.

HCPCS J-Codes: What Appears on Your Bill

COVID-19 vaccines do not use HCPCS Level II J-codes like infused biologics. Instead, Medicare and most payers bill the vaccine product and its administration under separate CPT codes for the 2026-2027 season.

Patient Assistance Programs

Pfizer and Moderna do not run manufacturer copay cards for their COVID-19 vaccines because insured patients already pay $0 by law. For uninsured patients, each manufacturer instead runs a separate no-cost access channel outside the standard insurance system.

Common COVID-19 Vaccine Billing Errors

If you were charged anything for a COVID-19 vaccine while covered by Medicare, Medicaid, or an in-network commercial plan, check for these common billing mistakes before paying.

• Cost-sharing applied to a Medicare Part B claim: your dose should show $0 patient responsibility, with no deductible or coinsurance, because COVID-19 vaccination is a Part B preventive benefit, not a Part D drug sitting on a formulary tier.
• Vaccine billed as an out-of-network self-pay charge when your in-network pharmacy or clinic administered it: ask the biller to resubmit through your insurance rather than accepting a cash-pay receipt.
• Wrong CPT product code used, for example Comirnaty's 91320 billed when you actually received Spikevax's 91322: this can trigger a coverage denial even though the vaccine itself was free.
• Administration fee (CPT 90480) charged twice for a single dose, once by the pharmacy and once by a separate clinical staffing company.
• Prescription requirement confusion: some pharmacies in certain states now require a prescription for patients outside the FDA-approved age or risk-condition group, and bill a separate office-visit fee if a prescription had to be written on-site.
• Uninsured patient charged full cash price without being told about Pfizer RxPathways or Moderna's Direct Relief and Project HOPE clinic network.

Frequently Asked Questions